KALV

KalVista Pharmaceuticals, Inc. (KALV) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Capital Allocation

Management maintains a strong liquidity position with a current ratio of 5.58x and cash ratio of 4.00x.

The balance sheet remains lightly levered on a net debt basis, with net debt to EBITDA at -0.47x.

Capital deployment appears conservative, with minimal capex intensity and no dividend payout.

Operational Execution

Gross margin remains very high at 92.0%, indicating strong product-level economics.

However, profitability is still deeply negative, with EBITDA margin at -101.1% and net margin at -119.4%.

Cash generation remains weak, with operating cash flow and free cash flow both negative on a TTM basis.

Governance And Incentives

No fresh news or disclosures indicate a material change in governance or incentive alignment this month.

Management assessment remains anchored to the existing operating and capital structure profile.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on KalVista Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →